Given the interest in developing ACLY inhibitors to treat many disorders, including hypercholesterolemia and cardiovascular disease, targeting the CSH module of ACLY may provide another viable site for drugging ACLY. The gene discussed is ACLY; the disease is familial hypercholesterolemia.